Celgene sales up 18% despite Abraxane lag; AZ, Teva to pay $54M in state Medicaid settlement;

@FiercePharma: U.S. FDA Form 483 has Indian drugmakers 'spooked'. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: If the quarterly Vivus trend keeps up, I'm pretty sure that we're about to find out they have zero remaining sales reps | Follow @CarlyHFierce

> Celgene ($CELG) posted a double-digit sales increase for Q3, despite declining sales of its cancer drug Abraxane, but earnings fell on acquisition costs. Release

> AstraZeneca ($AZN) and Teva Pharmaceutical Industries' ($TEVA) Cephalon unit agreed to pay a group of states $54 million to settle Medicaid price-reporting allegations; the drugmakers wrapped up similar allegations with the U.S. Justice Department earlier this year. Report

> The Indian generics maker Cipla saw net profits grow by 44% for its latest quarter, but that 4.31 billion rupee profit still lagged analyst estimates, thanks to increased expenses. Report

Medical Device News

@FierceMedDev:Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. Read more | Follow @FierceMedDev

@VarunSaxena2: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Biosensors sells out to Chinese private equity firm for $787M. Story | Follow @EmilyWFierce

> Allergan beefs up in aesthetics with implant purchase. Does M&A suitor Pfizer approve? Report

> Boston Scientific files patent infringement suit against Edwards' Sapien 3 TAVR. Story

> FDA adds another artificial kidney to its Expedited Access Pathway program. News

Biotech News

@FierceBiotech: GSK, Gates Foundation help immuno-oncology player to $56M Series A round. Story | Follow @FierceBiotech

@JohnCFierce: Relentless masochism... NYT story | Follow @JohnCFierce

> Bluebird slips as new data paints a cloudy picture for its gene therapy. Report

> Sanofi inks a $4.2B diabetes deal, playing pipeline catch-up with Novo and Lilly. Story

> FierceBiotech Radio on the latest Valeant drama, Pfizergan and Shire's latest buyout. Listen online

CRO News

> Icon eyes Asia growth with a pair of exec appointments. More

> Catalent ekes out revenue growth in the face of currency troubles. News

> PRA narrows its sales guidance on the way to a record year. Story

> Charles River boosts its 2015 outlook after strong sales quarter. Article

> WuXi pads its revenue on the way to a big buyout decision. More

Pharma Manufacturing News

> Turing again vows to cut drug's cost as compounder starts manufacturing a version. Story

> India's Torrent Pharma targets production from new plant at U.S., EU. More

> Pfizer will transfer manufacturing tech for Prevenar 13. News

> Novo starts in on massive production buildup. Article

> Novartis, others face higher manufacturing costs with CAR-T cell treatments. More

Pharma Asia News

> Indian drugmakers on the hunt for money and growth. More

> Australia looks to save cash by cutting scripts for common drugs. News

> Generic drugs cut costs by $254B in U.S. last year. Story

> AbbVie nears launch of Viekira into crowded Japan HCV battle. Article

> Roche gets temporary court injunction on Herceptin biosimilar in India. News

And Finally... The Generic Pharmaceutical Association (GPhA) said the U.S. healthcare system saved $254 billion last year by using lower-cost generics instead of branded meds. Report